Bioventus Inc. (BVS) intrinsic value & 10-year financials
Bioventus Inc. (BVS) has a Graham intrinsic value of $7.50 per share. At $13.30 on Oct 17, 2026, the stock trades 77% above that value. Over the last 8 fiscal years revenue grew 8.9% a year to $568.1M, with an average return on invested capital of -5.3%.
- Graham intrinsic value
- $7.50
- Share price (Oct 17, 2026)
- $13.30
- Price vs Graham value
- 77% above
- Market cap
- $916.6M
- Revenue (FY2025)
- $568.1M
- Revenue growth (8-yr CAGR)
- 8.9%
- ROIC (10-yr avg)
- -5.3%
- Free cash flow (FY2025)
- $72.1M
BVS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $568.1M | $22.7M | $0.33 | $72.1M | 9.5% | 12.0% |
| FY2024 | $573.3M | -$33.5M | -$0.52 | $37.8M | -2.1% | -2.0% |
| FY2023 | $512.3M | -$156.2M | -$2.49 | $8.0M | -16.0% | -12.9% |
| FY2022 | $512.1M | -$158.7M | -$2.59 | -$23.6M | -49.0% | -25.3% |
| FY2021 | $430.9M | $19.4M | -$0.15 | $15.6M | 2.8% | 1.5% |
| FY2020 | $321.2M | $16.4M | — | $67.7M | 6.6% | — |
| FY2019 | $340.1M | $6.9M | — | $38.4M | 9.2% | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bioventus Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bioventus Inc. has historically struggled to out-earn its cost of capital, averaging just -5.3% ROIC.
Bioventus Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Bioventus Inc. is modeled at 8.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $7.50 per share.